Tagraxofusp

證據等級: L5

預測適應症: 10 個

Tagraxofusp: From Blastic Plasmacytoid Dendritic Cell Neoplasm to Pre-Malignant Myeloid Neoplasm

One-Sentence Summary

Tagraxofusp is a CD123-targeted diphtheria-toxin fusion protein; per its own trial documentation it is used to treat CD123-expressing hematologic malignancies (established blastic plasmacytoid dendritic cell neoplasm and AML). Of TxGNN's top-10 predictions, 9 (including the #1-ranked "esotropia") were flagged by the evidence pipeline itself as mechanistic noise with zero supporting evidence. The only prediction with real supporting data is Pre-Malignant Myeloid Neoplasm (rank #2), backed by 5 clinical trials (all trials of tagraxofusp or closely related CD123-targeted agents) but no dedicated literature, and the trial populations largely target established AML/BPDCN rather than a strict pre-malignant population — so the link remains inferential.

Quick Overview

Item	Content
Original Indication	Blastic plasmacytoid dendritic cell neoplasm (BPDCN) — stated in trial documentation (NCT05476770); not yet confirmed via DrugBank/regulatory data, see Data Gap DG002
Predicted New Indication	Pre-Malignant Myeloid Neoplasm (e.g., MDS/CMML precursor states)
TxGNN Prediction Score	99.73%
Evidence Level	L3
Germany Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Note: The nominal #1-ranked prediction, "esotropia" (99.73% score), was excluded from this report — the evidence pipeline's own annotation states it has no mechanistic connection to CD123-targeted toxin therapy and no supporting trials/literature (classified as TxGNN similarity noise). The same applies to 8 of the remaining 9 top predictions (inner ear neoplasm, benign tongue neoplasm, non-seminomatous lesion, chondroid hamartoma, childhood bronchial carcinoid, ductal/ductular proliferation, cystic neoplasm, thyroglossal duct cyst) — all L5/S0/Hold with no biological rationale.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack (Data Gap DG002 — High severity). Based on trial documentation, tagraxofusp is a CD123-targeted diphtheria toxin fusion protein ("protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123"), and it is already used clinically against CD123-expressing hematologic malignancies (BPDCN, AML, high-risk MDS).

The proposed link to "pre-malignant myeloid neoplasm" rests on the biological premise that CD123 (IL-3Rα) is over-expressed not only on established leukemic blasts but also on abnormal stem/progenitor clones in pre-malignant myeloid conditions (e.g., MDS, CMML), meaning tagraxofusp could theoretically eliminate these clones before progression to overt malignancy.

However, this connection is explicitly flagged as inferential in the source data: none of the 5 supporting trials enroll a strictly-defined pre-malignant population. Most target established AML, BPDCN, or high-risk MDS (NCT03113643), or measurable residual disease in AML (NCT07148180) — a state closer to sub-clinical relapse than to a true pre-malignant lesion. Only NCT06414681 (tagraxofusp + pacritinib in myelofibrosis) touches an MDS/MPN-overlap population, and it has not yet begun recruiting.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06414681	Early Phase 1	Not yet recruiting	20	Tagraxofusp + pacritinib in intermediate-1+ myelofibrosis after/instead of JAK inhibitor therapy; Grade B relevance (MDS/MPN-overlap population, but not yet recruiting)
NCT05476770	Phase 1	Recruiting	54	Tagraxofusp ± chemotherapy in pediatric relapsed/refractory CD123+ hematologic malignancies; confirms tagraxofusp's approved use in BPDCN; Grade B relevance (established malignancy, not pre-malignant)
NCT07148180	Phase 1/2	Recruiting	31	Tagraxofusp + azacitidine + venetoclax targeting measurable residual disease (MRD) in AML; Grade B relevance (MRD-positive state partially overlaps with "pre-malignant" concept)
NCT03113643	Phase 1	Recruiting	72	SL-401 (= tagraxofusp) + azacitidine/venetoclax in relapsed/refractory AML, treatment-naive AML, BPDCN, and high-risk MDS; Grade B relevance (drug's own trial, but population is established malignancy)
NCT03386513	Phase 1/2	Active, not recruiting	179	IMGN632 (pivekimab sunirine, a different CD123-targeted agent) in CD123+ AML and hematologic malignancies; Grade C relevance (mechanism analogy only, not the same drug)

Literature Evidence

Currently no related literature available for this indication (the 20 literature records retrieved for a different predicted indication — "ductal or ductular proliferation" — concern hepatic ductular reaction/fibrosis pathways unrelated to CD123 biology and were excluded as apparent text-matching noise).

Germany Market Information

Tagraxofusp is currently not marketed in Germany (0 authorizations on record), so no product/authorization table is available.

Cytotoxicity

Tagraxofusp is a CD123-targeted immunotoxin (protein-drug conjugate incorporating a diphtheria toxin payload) used against CD123-expressing hematologic malignancies, meeting the antineoplastic criteria for this section.

Item	Content
Cytotoxicity Classification	Targeted therapy (CD123-directed protein-toxin conjugate; not a conventional cytotoxic chemotherapy agent)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are not yet available in this evidence pack — see Data Gap DG001, Blocking severity.)

Conclusion and Next Steps

Decision: Hold

Rationale: The only prediction with any supporting evidence (pre-malignant myeloid neoplasm) is backed solely by trials in established AML/BPDCN/high-risk MDS rather than a genuine pre-malignant population, and the mechanistic link is explicitly labeled inferential in the source data. Combined with a Blocking-severity data gap on TFDA/German label warnings and contraindications (DG001), the evidence does not clear the bar for S1 safety pre-screening, let alone a Go decision. All other top-10 TxGNN predictions for this drug were independently confirmed as biological noise with no clinical trial or literature support.

To proceed, the following is needed:

Package insert (warnings, contraindications, DDI) to clear the S1 safety pre-screen (DG001)
Confirmed mechanism of action data via DrugBank API (DG002)
A trial or cohort study specifically enrolling a pre-malignant (e.g., low/intermediate-risk MDS, CMML) population rather than established AML/BPDCN, to directly test the CD123-clearance hypothesis
Results from NCT06414681 (myelofibrosis combination trial) once recruitment begins, as the closest available population match
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.